Innotech renews manufacturing license
21 September 2021
R&D Center NovaMedica Innotech has successfully passed the audit of the Ministry of Industry and Trade and received a renewed and extended manufacturing license for production of pharmaceutical drugs, which creates new contracting opportunities and, in addition to the already existing services, allows carrying out primary and secondary packaging of biological products.
NovaMedica signed an agreement with Bayer on transfer of exclusive rights to its product
31 May 2021
Russian pharmaceutical company NovaMedica (part of the RUSNANO portfolio) and the corporation Bayer signed an agreement to provide Bayer with an exclusive license to commercialization of an innovative product developed by NovaMedica, including its manufacturing and promotion.
R&D Center NovaMedica Innotech joined Avifavir production efforts in Russia
04 March 2021
R&D Center NovaMedica Innotech (subsidiary of the pharmaceutical company NovaMedica, investment project of RUSNANO) announced release of the first commercial batch of the anti-COVID drug Avifavir® under the partnership with Kromis LLC, joint venture of the Russian Direct Investment Fund (RDIF) and the company ChemRar. NovaMedica Innotech will manufacture 100,000 units of Avifavir per month.
03 March 2021
We have already made a tradition of guided tours to the R&D Center NovaMedica Innotech for our most curious and precious visitors – children who come to see what their mothers and fathers do at work.
24 December 2020
NovaMedica team wishes you Happy Holidays! Harmony and joy to you and your loved ones. We wish you to be cheerful and healthy, creative and enthusiastic!
Pharmaceutical Forum 2020. New is the understudied old
04 December 2020
Rustam Iksanov, Vice President for R&D at NovaMedica, believes one of the most important trends in development of the modern pharmaceutical market to be supergenerics. He spoke about this in his address at the Russian Pharmaceutical Forum in Moscow.
Pharmaceutical Forum 2020. Key points first hand
01 December 2020
24-25 ноября Институт Адама Смита провел важнейшее для российской фарминдустрии мероприятие – Российский фармацевтический форум. Одну из наиболее важных панелей Форума – «ФАРМАЦЕВТИКА БУДУЩЕГО В РОССИИ И В МИРЕ: ГЛОБАЛЬНЫЙ ВЗГЛЯД НА ТРАНСФОРМАЦИЮ ОТРАСЛИ» - модерировала гендиректор НоваМедики Елена ЛИТВИНОВА. Она поделилась своими впечатлениями о ходе дискуссии и о проблемах отрасли, которые вскрыл ФармФорум.
Four top managers of NovaMedica make it to the TOP 1000 Russian Managers 2020
15 September 2020
Four top managers of the pharmaceutical company NovaMedica were named among the business leaders in the annual Top 1000 Russian Managers rating published by the Russian Managers Association and the Kommersant Publishing House.
NovaMedica will continue working remotely
20 March 2020
Health and safety of patients, our employees and their families take the highest priority for NovaMedica. As the COVID-19 situation is developing rapidly, we follow the recommendations of the federal and local authorities to prevent the infection from spreading. On March 19, NovaMedica started operating remotely.
Marina Egorova to take charge of commerce and marketing at NovaMedica
20 November 2019
Russian pharmaceutical company NovaMedica announces the appointment of Marina Egorova, formerly director of business development, as head of the company’s commercial unit. Yulia Sobakina, who was in charge of commerce and marketing at NovaMedica since November 2017, will move on to assume the position of commercial director at Magnit Pharma LLC.
NovaMedica will produce migraine drug Relonova in Moscow
23 March 2023
A resource for anti-tumor drugs testing has been launched in Russia
23 March 2023
Building a Community of Trust in Epilepsy & Rare Syndromes
23 March 2023
Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome
22 March 2023